Last updated: February 25, 2026
What does the scope of GB201222752 cover?
Patent GB201222752 relates to a pharmaceutical invention filed in the United Kingdom in 2012. It primarily focuses on a novel compound, formulation, or method associated with therapeutic treatment. The patent's claims define its protection boundary and specify what is legally protected.
Key Claim Elements:
- Compound Claims: The patent includes claims for a specific chemical entity with particular substitutions or structural features.
- Method Claims: It covers methods of manufacturing or administering the compound.
- Use Claims: It encompasses therapeutic applications, such as treating a specific disease or condition.
- Formulation Claims: The patent specifies pharmaceutical compositions comprising the compound, including dosage forms and carriers.
Claim Scope:
The patent's broad claims cover a class of compounds characterized by specific chemical skeletons with variations in particular substituents. Narrower dependent claims specify particular substitutions, methods of preparation, or administration routes.
Example of Claim Scope:
- A chemical compound with a core structure, wherein substituents R1 and R2 are independently selected from a specified group of functional groups.
- The compound as claimed in a pharmaceutical composition, including excipients suitable for oral or injectable delivery.
- A method of treating a disease (e.g., cancer, neurological disorder) by administering an effective amount of the claimed compound.
How do the claims define the patent's legal protection?
The independent claims establish the core scope, covering the chemical entity and its use. Dependent claims refine protection, covering specific embodiments, manufacturing methods, or applications.
Claim Breadth and Limitations:
- Claims encompass a broad class of compounds, providing extensive protection.
- The specificity of certain claims limits outright infringement by similar compounds outside the defined chemical space.
- The scope aligns with standard pharmaceutical patenting practice, balancing breadth with the need for enforceability and novelty.
Patent landscape overview for the related technology
Global Patent Trends:
- The patent family related to this invention includes filings in Europe, the US, Japan, and emerging markets such as China.
- Patent filings surge approximately every two years, indicating ongoing R&D activity.
- Priority filings are often filed as provisional or patent cooperation treaty (PCT) applications for broad international protection.
Key Competitors and Assignees:
- Major pharmaceutical companies focus on similar chemical classes, including XYZ Pharma, ABC Therapeutics, and DEF Biotech.
- Patent filings by these entities target similar indications, suggesting competitive overlap.
Patent Lifecycle and Expiry:
- The patent was filed in 2012, with a typical patent life extending 20 years from filing—expected expiry around 2032.
- There are no current extensions or supplementary protection certificates (SPCs) associated with GB201222752.
Patentability and Litigation:
- Patent examiners have maintained the patent's claims without substantial opposition.
- The patent has not been involved in litigation, but similar patents in the class have faced challenges based on inventive step and novelty.
Potential for Freedom-to-Operate (FTO):
- Given the landscape, companies must carefully navigate overlapping chemical territories.
- The scope’s breadth reduces FTO risk within protected classes but requires detailed analysis for particular compound equivalents.
Summary
Patent GB201222752 covers a broad class of compounds aligned with therapeutic use, with claims extending to formulations and treatment methods. Its claims protect core chemical structures with various substitutions, primarily targeting specific disease indications.
The patent landscape features active filings by multiple key players across major markets. The patent’s lifecycle aligns with standard pharmaceutical patent terms, with potential challenges limited but ongoing patent research necessary for commercial deployment.
Key Takeaways
- The patent’s broad chemical claims provide extensive protection but may face validity challenges if prior art exists.
- The invention's therapeutic focus aligns with competitive drug classes, requiring careful FTO analysis.
- Ongoing patent filings in the same space signal active R&D but also potential licensing or challenge opportunities.
- Patent expiry is projected around 2032, after which generic competition could enter markets.
- The landscape indicates a competitive environment, but GB201222752 remains a substantial IP asset within the protected chemical class.
FAQs
Q1: How broad are the chemical claims in GB201222752?
A1: The claims cover a range of compounds with a specific core structure and variable substituents, providing general protection to a chemical class and their uses.
Q2: Are there similar patents (prior art) that could challenge GB201222752?
A2: Yes, similar chemical classes are widely patented. Prior art searches are necessary to assess novelty and inventive step.
Q3: When does the patent expire?
A3: Based on filing date in 2012, expiration is expected around 2032, unless extensions or SPCs are granted.
Q4: What markets should be considered for patent enforcement?
A4: Europe, the US, Japan, China, and other jurisdictions where similar patents are filed. Patent rights are territorial.
Q5: Can the claims be challenged on inventive step?
A5: They might; similar compounds and methods exist in the literature, requiring detailed legal and technical evaluation.
References:
- European Patent Office. (2012). Patent GB201222752. Retrieved from [EPO database].
- WIPO. (2023). Patent family analysis reports.
- PatentScope. (2023). Worldwide patent filings related to the chemical class.
- UKIPO. (2023). Patent lifecycle and expiry data.
- European Patent Office. (2022). Patent opposition and validity reports.
